Clinical trials: Plasmapheresis
COVID19
Study of Plasma Exchange in Severe COVID-19
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain.
- Trial name
- COVIPLEX (NCT04623255)
- Testing
- OCTAPLAS
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University College, London
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with…
- Trial name
- NCT02872142
- Testing
- Albutein 5%, Plasma Exchange
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Grifols Therapeutics LLC
Primary Heart Transplant, Heart Transplantation
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
The primary objective is to evaluate the efficacy of desensitization therapy, which includes VELCADE® (bortezomib) and plasmapheresis, on select sensitized patients awaiting heart transplantation.
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Trial name
- NCT01769443
- Testing
- bortezomib, plasmapheresis
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Thrombotic Thrombocytopenic Purpura
Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
The purpose of the study is to find out if administration of danazol with plasma exchange and corticosteroids will reduce the number of plasma exchanges required to control Thrombotic Thrombocytopenic Purpura (TTP).
- Trial name
- TTP (NCT00953771)
- Testing
- Danazol
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Kidney Transplant Rejection
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients.
- Trial name
- NCT04711850
- Testing
- Imlifidase
- Where
- 7 sites in Austria, France and 1 more
- Volunteers
- 18 people
- Sponsor
- Hansa Biopharma AB
Apheresis Related Hypotension
IMPACT (Improving Plasma Collection) Clinical Trial
Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.
- Trial name
- IMPACT (NCT04320823)
- Testing
- Updated Plasma Collection Feature, Current Plasma Collection Approach
- Where
- 3 sites in United States
- Volunteers
- 3,443 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5% albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02479802
- Testing
- Albumin
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Instituto Grifols, S.A.
Thrombotic Thrombocytopenic Purpura
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by small blood clots throughout the body that can damage major organs and cause death. TTP is treated with plasma exchange (also called "plasmapheresis").
- Trial name
- NCT01554514
- Testing
- rituximab
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Acute-On-Chronic Liver Failure
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects.
- Trial name
- APACHE (NCT03702920)
- Testing
- SMT + PE-A 5%, Standard Medical Treatment
- Where
- 30 sites in United States, Austria and 7 more
- Volunteers
- 274 people
- Sponsor
- Instituto Grifols, S.A.
Thrombotic Thrombocytopenic Purpura
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary…
- Trial name
- MAYARI (NCT05468320)
- Testing
- Caplacizumab, Corticosteroids, anti-CD20 antibody
- Where
- 27 sites in United States, Belgium and 9 more
- Volunteers
- 51 people
- Sponsor
- Sanofi
Adverse Effects in the Therapeutic Use of Plasma Substitutes
Octaplas Pediatric Plasma Exchange Trial
To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring…
- Trial name
- Octaplas (NCT01938378)
- Testing
- Octaplas™
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Octapharma
Focal Segmental Glomerulosclerosis
Permeability Factor in Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a renal syndrome characterized by proteinuria (usually nephrotic range), limited response to conventional therapy, and a poor renal prognosis, with progression to end stage renal…
- Trial name
- NCT00007475
- Testing
- Plasma exchange, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Multiple Sclerosis
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis
- Trial name
- IMPAMS (NCT01214317)
- Testing
- plasmapheresis
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04973488
- Testing
- Therapeutic plasma exchange
- Where
- Romania
- Volunteers
- 38 people
- Sponsor
- Novacescu Alexandru
Thrombotic Thrombocytopenic Purpura
Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD
- Trial name
- NCT00713193
- Testing
- Cyclosporine, Prednisone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ohio State University
Autoimmune Diseases, Renal Disorders
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma Exchange (TPE) is prescribed by their physicians.
- Conditions
- Autoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
- Trial name
- NCT01210716
- Testing
- Therapeutic plasma exchange
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fenwal, Inc.
Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
The purpose of this study is to determine whether plasma exchange as well as immunosuppressive therapy are effective in reducing death and end-stage renal disease (ESRD).
- Trial name
- PEXIVAS (NCT00987389)
- Testing
- Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose]
- Where
- 98 sites in United States, Australia and 13 more
- Volunteers
- 704 people
- Sponsor
- University of Pennsylvania
COVID-19
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
This is a phase II randomized study of convalescent plasma for the treatment of non-immune individuals with COVID-19 infection at high risk of complications.
- Trial name
- NCT04456413
- Testing
- Convalescent Plasma, Best Supportive Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hackensack Meridian Health
COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
- Trial name
- NCT04343755
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Hackensack Meridian Health